The combination of ezetimibe and statins can lead to an increase in aminotransferase, which can lead to liver impairment with prolonged use; it can lead to myalgia and, in severe cases, rhabdomyolysis. When the patient is not effective with lipid-regulating drugs alone, the two can be used in combination to lower cholesterol levels. It is used clinically for primary hypercholesterolemia and pure familial hypercholesterolemia. 1. Ezetimibe can reduce serum cholesterol level by inhibiting cholesterol absorption. The administration of this product may result in adverse reactions such as abdominal pain, diarrhea, abdominal distension, headache and fatigue, impaired hepatic function, myalgia, back pain, muscle weakness, loss of appetite, and elevated blood pressure. Note that active liver disease, the emergence of unexplained elevation of serum aminotransferases, pregnant and lactating women are prohibited. 2. Statins play a role in lowering serum cholesterol levels by inhibiting cholesterol synthesis. The use of the drug can lead to nausea and diarrhea, myalgia, arthralgia, pain in the limbs, elevated aminotransferase, urinary tract infections and other adverse reactions. Note that active liver disease, unexplained elevated aminotransferases, pregnancy and lactation are contraindicated. Patients must use the drug under the guidance of a professional physician, do not combine or change the dose without authorization, and strictly comply with medical advice.